文献速递炎症性肠病

炎症性肠病患者再入院风险因素及干预措施的系统评价与荟萃分析

Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-08-27

该系统评价纳入17项队列研究共6324例接受内科治疗的成人IBD住院患者,采用随机效应荟萃分析估算再入院率。30天再入院率为18.1%(95%CI 14.4-22.4),90天为26.0%(95%CI 22.7-29.6)。再入院常见原因为IBD flare、感染或非计划手术并发症;疼痛控制入院、出院时需全肠外营养及既往或住院期间非计划手术为一致风险因素。仅1项研究聚焦干预措施。

要点

  • IBD患者30天再入院率为18.1%,90天为26.0%。
  • 再入院常见原因为IBD flare、感染或非计划手术并发症。
  • 疼痛控制入院、出院需全肠外营养及非计划手术为30天再入院风险因素。

核心结论

  • 接受内科治疗的IBD患者30天和90天再入院率分别为18.1%和26.0%。
  • IBD flare和感染是再入院的常见原因,疼痛控制不足和需肠外营养是常见风险因素。
  • 需要开展干预性研究以降低再入院风险。

研究设计与样本

  • 系统检索截至2018年7月1日的文献,最终纳入17项队列研究共6324例接受内科治疗的成人IBD住院患者。
  • 采用随机效应荟萃分析估算30天和90天再入院率,并定性分析聚焦减少再入院的干预研究。

主要发现

  • 30天再入院率为18.1%(95%CI 14.4-22.4),90天再入院率为26.0%(95%CI 22.7-29.6)。
  • 荟萃回归显示,溃疡性结肠炎患者比例高于克罗恩病的研究报告再入院风险更高。
  • 再入院最常见原因为IBD flare、感染或住院期间非计划手术的并发症。
  • 30天再入院一致风险因素:因疼痛控制入院(OR 2.27;95%CI 1.69-3.03)、出院时需全肠外营养(OR 2.13;95%CI 1.36-3.35)、既往或住院期间非计划手术(OR 3.11;95%CI 2.27-4.25)。
  • 仅1项研究聚焦干预措施(专科住院IBD服务)以降低再入院风险。

关键数值与推荐

  • 30天再入院率18.1%(95%CI 14.4-22.4)。
  • 90天再入院率26.0%(95%CI 22.7-29.6)。
  • 因疼痛控制入院OR 2.27(95%CI 1.69-3.03)。
  • 出院时需全肠外营养OR 2.13(95%CI 1.36-3.35)。
  • 既往或住院期间非计划手术OR 3.11(95%CI 2.27-4.25)。

临床怎么用

  • 识别因疼痛控制入院、出院时需全肠外营养及有非计划手术史的IBD住院患者可能再入院风险较高。
  • 关注IBD flare、感染及非计划手术并发症作为再入院的常见原因。
  • 目前仅1项研究评估了专科住院IBD服务对减少再入院的作用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We investigated 30- and 90-day rates and causes of, risk factors for, and interventions to reduce hospital readmission in patients who received medical treatment for inflammatory bowel diseases (IBD). METHODS: We performed a systematic search of publications through July 1, 2018 for studies of rates of hospital readmission and associated causes and risk factors in patients who received medical treatments for IBD. Our final analysis included 17 cohort studies (6324 patients) of hospitalized adults with IBD who had received medical treatment, along with reported readmission rates with detailed chart review. We performed random effects meta-analysis to estimate 30- and 90-day rates of readmission and identified causes and risk factors associated with readmission. We also performed qualitative analyses of studies that focused on interventions to reduce readmission. RESULTS: Overall, the 30-day rate of readmission was 18.1% (95% CI, 14.4-22.4) and the 90-day rate was 26.0% (95% CI, 22.7-29.6). On meta-regression, studies with higher proportions of patients with ulcerative colitis than Crohn's disease reported higher risks for readmission. Most common reasons for readmission were IBD flare, infection, or complications from unplanned surgeries during hospitalizations. Consistent risk factors for 30-day readmission were admission for pain control (odds ratio [OR], 2.27; 95% CI, 1.69-3.03), need for total parenteral nutrition on discharge (OR, 2.13; 95% CI, 1.36-3.35), and prior or unplanned surgery during admission (OR, 3.11; 95% CI, 2.27-4.25). Only 1 study focused on interventions (specialized inpatient IBD service) to reduce risk of readmission. CONCLUSIONS: Overall 30- and 90-day rates of readmission for patients who received medical treatment for IBD are 18.1% and 26.0%, respectively. IBD flares and infections are common reasons for readmission, and inadequate pain control and need for parenteral nutrition were common risk factors. Interventional studies to reduce risk of readmission are needed.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Nguyen NH, Koola J, Dulai PS, et al. Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019. PMID: 31470176. doi:10.1016/j.cgh.2019.08.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。